cabozantinib,atezolizumab
roche
['contact03', 'cabo ', 'congrat', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
the omnipotent presents #contact03, cabo-atezo vs cabo in rcc, did not improve 1o pfs or os. many lessons learned &amp; importantly 1st trial sequencing p.d.-1 based therapy after prior io therapies. congrats on simult pub &amp;team! #asco23 
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe